Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3085% above fair value
$13.45+0.12 (+0.90%)
Close on Nov 19, 2026Market cap $471.65MP/E –Yield –
Fennec Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2013 it was -$2.21M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | -$2.21M | – |
| FY2012 | Dec 31, 2012 | -$2.99M | – |
| FY2011 | Dec 31, 2011 | -$3.23M | – |
See a number that looks wrong?